Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?
Open accessThe DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Abstract
Background: Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Thus, it seems crucial to explore complementary therapeutic approaches. Genome-wide association studies identified robust associations between AD and several AD risk genes related to immune response, including but not restricted to CD33 and TREM2 . Here, we critically reviewed the current knowledge on candidate neuroinflammatory biomarkers and their role in characterizing the pathophysiology of AD. Main body: Neuroinflammation is recognized to be a crucial and contributing component of AD pathogenesis. The fact that neuroinflammation is most likely present from earliest pre-stages of AD and co-occurs with the deposition of Aβ reinforces the need to precisely define the sequence and nature of neuroinflammatory events. Numerous clinical trials involving anti-inflammatory drugs previously yielded unfavorable outcomes in early and mild-to-moderate AD. Although the reasons behind these failures remain unclear, these may include the time and the target selected for intervention. Indeed, in our review, we observed a stage-dependent neuroinflammatory process in the AD brain. While the initial activation of glial cells counteracts early brain Aβ deposition, the downregulation in the functional state of microglia occurs at more advanced disease stages. To address this issue, personalized neuroinflammatory modulation therapy is required. The emergence of reliable blood-based neuroinflammatory biomarkers, particularly glial fibrillary acidic protein, a marker of reactive astrocytes, may facilitate the classification of AD patients based on the ATI(N) biomarker framework. This expands upon the traditional classification of Aβ (“A”), tau (“T”), and neurodegeneration (“N”), by incorporating a novel inflammatory component (“I”). Conclusions: The present review outlines the current knowledge on potential neuroinflammatory biomarkers and, importantly, emphasizes the role of longitudinal analyses, which are needed to accurately monitor the dynamics of cerebral inflammation. Such a precise information on time and place will be required before anti-inflammatory therapeutic interventions can be considered for clinical evaluation. We propose that an effective anti-neuroinflammatory therapy should specifically target microglia and astrocytes, while considering the individual ATI(N) status of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Presently ongoing clinical trials in AD by mechanism of action of the tested agents. Twenty-five trials are testing anti-neuroinflammatory agents. AD Alzheimer disease, APOE Apolipoprotein E. Modified from Cummings et al. Alzheimers Dement (N Y). 2024 [12]](https://figures.cochat.ai/paper-figures/3a93f15fa711472098db4df4669c5492/tracking-neuroinflammatory-biomarkers-in-alzheimers-disease-a-strategy-for-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activated microglia surround amyloid plaques in the brains of both human patients with AD and mouse models of Aβ amyloidosis13,15,21,22.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971 · cited 2×
“Furthermore, considering that neurotoxic reactive astrocytes are stimulated by activated microglia [117], the availability of a biomarker for activated microglia becomes essential in identifying individuals who are at a higher risk of developing AD.”
BackgroundNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · cited 1×
“Accordingly, blood GFAP concentrations have already been successfully employed as a biomarker in clinical trials evaluating anti-Aβ monoclonal antibodies, such as lecanemab [148] and donanemab [149].”
MethodA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 1×
“The binding of TREM2 to ligands, including anionic lipids, lipoproteins, and Aβ, initiates downstream signaling cascades that promote microglial survival, proliferation, chemotaxis, and phagocytosis [43, 44].”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932 · cited 1×
“A recent phase III clinical trial evaluated the efficacy of donanemab, a monoclonal antibody targeting a pyroglutamate form of Aβ, in individuals with prodromal AD and mild dementia due to AD [5].”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“The significance of TREM2 in the pathogenesis of AD was underscored by the discovery of a specific heterozygous mutation, R47H, which substantially elevates the risk of developing LOAD [45, 46].”
BackgroundDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 1×
“…more recently, with donanemab—a potent anti-Aβ(p3-42) monoclonal antibody—exclusively enrolled patients who, as confirmed by [ 18 F]flortaucipir-PET scans, exhibited pathologic tau deposition (> 1.10 SUVR), but with quantitative tau levels below a specific upper threshold (1.46 SUVR) [151].”
BackgroundInfluentialTREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263
A Meta-Analysis of Cytokines in Alzheimer's Disease
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108 · cited 1×
“…which included 54 studies measuring cytokine concentrations (40 in peripheral blood and 14 in the CSF), patients with AD exhibited higher concentrations of IL-6, TNF-α, IL-1β, TGF-β, IL-12, and IL-18 in peripheral blood, and elevated levels of TGF-β in CSF, compared to healthy controls [141].”
Background
Cited by
Kamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., S, S., Singh S, A., & Prajapati, B. G. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.005 · Cited by 90
Neuroinflammatory Biomarkers in Alzheimer’s Disease: From Pathophysiology to Clinical Implications
Roveta, F., Bonino, L., Piella, E. M., Rainero, I., & Rubino, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211941 · Cited by 89
“Astrocytes are vital for synapse formation and regulating neurotransmitter release, particularly maintaining glutamate balance in the brain [2].”
InfluentialBiomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 87
“GFAP is a measure of reactive astrocyte activity and has been associated with neuroinflammation, suggesting GFAP levels as a potential target engagement in neuroinflammation target trials 177 .”
Cacabelos, R., Martínez-Iglesias, O. A., Cacabelos, N., Carrera, I., Corzo, L., & Naidoo, V. (2024) · Life · doi:10.3390/life14121555 · Cited by 40
Glial Cell Dynamics in Neuroinflammation: Mechanisms, Interactions, and Therapeutic Implications
García‐Domínguez, M. (2026) · Biomedicines · doi:10.3390/biomedicines14010115 · Cited by 36
“…central inflammatory responses and imaging-detected side events (e.g., edema or microhemorrhages), reminiscent of amyloid-related imaging abnormalities (ARIA) reported with anti-amyloid antibodies, underscore the potential risks associated with broad modulation of immune functions in the CNS [200].”
Metadata
- Authors
- Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., Malaguti, M., Melchiorri, D., Santos-Lozano, A., Imbimbo, C., Heneka, M. T., & Caraci, F.
- Affiliations
- Universidad Europea Miguel de Cervantes (ES)
- Chiesi (Italy) (IT)
- University of Catania (IT)
- University of Bologna (IT)
- Sapienza University of Rome (IT)
- University of Pavia (IT)
- University of Luxembourg (LU)
- Corresponding author
- Lista, Simone
- Heneka, Michael T.
- Caraci, Filippo
- ORCID
- Venue
- Journal of Neuroinflammation
- Published
- 2024-07-30
- Volume
- 21
- Issue
- 1
- Pages
- 187-187
- ISSN
- 1742-2094 (ISSN-L)
- PMC
- PMC11289964
- OpenAlex
- W4401107572
- Cited by
- 81
- References
- 179
- Citations by year
- 2026: 30 · 2025: 46 · 2024: 5
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Neuroinflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Funders
- Ministerio de Ciencia e Innovación (FPU19/02117)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neuroinflammation, neuroinflammatory biomarkers, microglia, astrocytes, glial fibrillary acidic protein, anti-inflammatory therapy, anti-amyloid beta monoclonal antibody, CD33, TREM2, blood-based biomarkers, disease staging, personalized treatment, longitudinal biomarker dynamics
- MeSH terms
- Neuroinflammatory Diseases, Alzheimer Disease, Animals, Humans, Biomarkers, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches? https://app.cochat.ai/papers/10.1186/s12974-024-03163-y
- The paper
- Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., Malaguti, M., Melchiorri, D., Santos-Lozano, A., Imbimbo, C., Heneka, M. T., & Caraci, F. (2024). Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches? Journal of Neuroinflammation. https://doi.org/10.1186/s12974-024-03163-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.